The well-known organization Beike Biotechnology Co., Ltd. at Shenzhen in China today has announced here that it recently carried out an investigative study at its collaborating hospital in the Shenyang province. The Company stated in this regard that the investigative study gives a crystal clear design of the ample presence of evidence of clinical efficacy, in conjunction with safety, and practicability of transplantation of peripheral blood stem cells for patients affected highly with peripheral vascular disease of the lower extremities. It is to be noted, from the available info on behalf of the Company that the Beike Biotechnology Co., Ltd. has had an affluent account of experience in the stream of research and the gradual treatment of vascular diseases with adult stem cells, which has chiefly happened through its alliance with Shenyang 463 hospital. Furthermore, as total number of 152 patients affected with the peripheral vascular disease of the lower extremities were signed up in the non-controlled study between the specific time period from the month of November, 2003 to that of March in the year 2006.

It was at the same period when a second study was completed that dealt chiefly with the notion of comparing the relative improvement of lower limb ischemia or the lack of blood supply, between transplantation of autologous peripheral blood stem cells and transplantation of bone marrow stem cells.

By the side of 12 weeks, the most important symptoms, that included the lower limb pain and coldness, showed definite signs of significant improvement in 137 of the patients happening to be 90.1 percent. There was also the specific advancement in the limb ulcers with the core improvement or healing in 46 (86.8 percent) of the 53 patients, while 25 of the 48 (47.9 percent) patients with limb gangrene showed also steady signs of slow but sure improvement. The X-rays that were carried out before treatment and at 12 weeks after treatment on 10 of the patients also was the major evidence for the formation of new collateral vessels.

Dr. Yang Xiao Feng, the Director of the stem cell program for vascular diseases at Shenyang 463 Hospital said through a press statement, "These preliminary results, while encouraging, must be further researched in future controlled studies and reinforced by separate studies by other laboratories."  

The chairman of the Beike Biotechnology group also said on the same occasion, "There is evidence demonstrating significant improvement in the quality of life of patients receiving the treatment, including formation of new collateral vessels." "We are now working to collaborate with institutions in the U.S. to further substantiate this and other studies including those we are doing for neurological diseases using umbilical cord stem cells," he concluded.